Physician profile
Alyssa M Shaffer
NPI 1750825170
$2,960.70
in general payments reported to CMS, 2019-2025
16 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $901 · 2023: $1,376 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.75 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $361.85 | 2023 | Stelara |
| Janssen Biotech, INC. | $346.87 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $153.24 | 2023 | |
| Ardelyx, INC. | $133.86 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $132.47 | 2022-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $108.28 | 2021 | |
| Celgene Corporation | $82.40 | 2022-2023 | Zeposia |
| Revance Therapeutics, INC. | $70.46 | 2025 | Daxxify |
| Pfizer INC. | $63.39 | 2023 | |
| Ironwood Pharmaceuticals, INC | $57.47 | 2022-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.35 | 2022-2023 | Xifaxan |
| Organon LLC | $42.46 | 2023 | Renflexis, Hadlima |
| Regeneron Healthcare Solutions, INC. | $21.75 | 2022 | |
| Sandoz INC. | $18.62 | 2023 | Hyrimoz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.